siNA Molecules Inhibit HBV Gene Expression via RNA Interference
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Hepatitis B are limited due to ineffectiveness, severe side effects, and the development of drug-resistant variants, necessitating new approaches to treat HBV infection.
Innovation Solution
The use of novel short interfering nucleic acid (siNA) molecules, including siRNA, dsRNA, miRNA, and shRNA, to modulate HBV gene expression through RNA interference, targeting conserved regions of the HBV genome for high potency and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current chemotherapeutic treatments (lamivudine, adefovir, entecavir, telbivudine) are used to prevent HBV replication, then viral replication is blocked, but drug-resistant HBV variants develop after prolonged treatment
Solution Approach 1:
Instead of using conventional chemotherapeutic agents that target viral polymerase, the patent employs RNA interference technology that uses small interfering RNA (siRNA) to target and degrade viral mRNA transcripts. This inverted approach—attacking the virus at the RNA level rather than the protein level—bypasses the mechanism that leads to drug resistance, as the siRNA targets conserved genomic regions that are less prone to mutation without losing function
Solution Approach 2:
The patent changes the therapeutic parameter from small-molecule chemotherapeutics to nucleic acid-based siRNA molecules. This parameter change enables targeting of multiple viral genes simultaneously (including pregenomic RNA, S gene, and other conserved regions), creating a multi-target approach that prevents the virus from developing resistance through single-point mutations
2Reliability
If pegylated Interferon-alpha2a is used to treat Hepatitis B, then some patients respond to treatment, but severe side effects occur and not all patients are effective
Solution Approach 1:
The patent uses siRNA as an intermediary molecule that mediates gene silencing through the RNA-induced silencing complex (RISC). This intermediary approach allows for precise, sequence-specific targeting of viral transcripts without the non-specific immunomodulatory effects of interferon, thereby achieving antiviral activity with reduced side effects
Solution Approach 2:
The siRNA molecules are designed as short-lived, disposable therapeutic agents that can be administered periodically. Unlike interferon which requires prolonged treatment and causes cumulative side effects, the siRNA approach allows for controlled, intermittent dosing that maintains efficacy while minimizing adverse effects
3Object-affected harmful factors
If vaccines are used for HBV prevention, then infection is prevented, but already infected patients cannot be treated
Solution Approach 1:
The patent transitions from the static, preventive-only vaccine approach to a dynamic therapeutic approach using siRNA. The siRNA can be administered systemically or locally to actively silence viral gene expression in infected patients, providing adaptability for both prevention and treatment scenarios that vaccines cannot achieve
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siNA molecules effectively inhibit HBV gene expression, providing a potential treatment for Hepatitis B and associated conditions like liver disease and cancer, offering an alternative to existing therapies.
Implementation Method 1
Alteration of viral gene expression, specifically HBV gene expression, through RNA interference (hereinafter 'RNAi') is one approach for meeting this need. RNAi is induced by short single-stranded RNA ('ssRNA') or double-stranded RNA ('dsRNA') molecules.
Data Source
AI summary
The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of HBV gene expression and/or activity, and/or modulate a HBV gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against HBV gene expression.